Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment of hormone-positive metastatic breast cancers (mBCs). They are currently established as standard therapies in combination with endocrine therapy as first- and second-line systemic treatment options for both endocri...

Descripción completa

Detalles Bibliográficos
Autores principales: Asghar, Uzma S., Kanani, Ruhi, Roylance, Rebecca, Mittnacht, Sibylle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769124/
https://www.ncbi.nlm.nih.gov/pubmed/35005994
http://dx.doi.org/10.1200/PO.21.00002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769124/
https://www.ncbi.nlm.nih.gov/pubmed/35005994
http://dx.doi.org/10.1200/PO.21.00002

Ejemplares similares